First-in-human universal flu vaccine trial begins

The first-in-human trial of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple influenza virus strains has begun.

The Phase I trial (NCT04896086) will assess the safety and immunogenicity of the experimental vaccine, FluMos-v1, and compare it to a licensed seasonal quadrivalent influenza vaccine in 35 healthy participants aged 18 to 50 years old. The study is being conducted at the National Institutes of Health Clinical Center in Bethesda, Maryland, US, and led by Dr Alicia Widge of US National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC).

“The health and economic burdens of influenza are substantial and the world badly needs improved flu vaccines,” said NIAID Director Dr Anthony Fauci. “I am encouraged by the great promise of the VRC nanoparticle vaccine candidate, which so far has performed very well in pre-clinical testing.”

Standard influenza vaccines must be reformulated and administered annually to match changes in the influenza virus hemagglutinin (HA) protein in the viral strains predicted to dominate in the upcoming influenza season. If the vaccine is not well matched to dominant circulating virus strains, the antibodies elicited may provide sub-optimal protection. To overcome this issue, so-called ‘universal’ influenza vaccines are being developed and tested by many research groups to see if they could one day eliminate the need for annual vaccination by generating long-lasting antibodies to protect against many existing or emergent influenza virus strains, including those not represented in the vaccine.

Similar to commercially available quadrivalent flu vaccines, the experimental nanoparticle FluMos-v1 vaccine is designed to elicit antibodies directed against the HA protein from four different virus strains, two influenza type A strains of H1 and H3 subtype and two influenza type B strains. However, unlike conventional flu vaccines, FluMos-v1 displays multiple copies of each of the four HA types. In total, the FluMos-v1 vaccine displays 20 HA epitopes, arrayed in repeating patterns on its self-assembling nanoparticle scaffolds.

In their recently published animal study, VRC scientists led by Dr Barney Graham, Dr Masaru Kanekiyo and their collaborators from the University of Washington tested the investigational nanoparticle vaccine in mice, ferrets and monkeys – and compared the immune responses generated to those made by a commercially available seasonal flu vaccine. FluMos-v1 performed as well as or slightly better than the commercial vaccine in eliciting antibodies matched to the vaccine’s HA components. FluMos-v1 vastly outperformed the seasonal flu vaccine in its ability to elicit protective antibodies to two influenza type A subtypes (H5 and H7) not in the vaccine. 

The clinical trial aims to enrol 35 participants in total: 15 will receive a single intramuscular injection of a US Food and Drug Administration (FDA)-licensed quadrivalent seasonal flu vaccine; five will receive a 20µg dose of the investigational vaccine by intramuscular injection; and, if there are no safety concerns detected at that dosage, an additional 15 volunteers will receive one 60µg dose of the investigational vaccine.

Participants will keep a diary for a week following vaccination in which to report any signs or symptoms, including redness, pain or swelling at the injection site, tiredness, headache, muscle aches or joint pain. All volunteers will record their temperature daily and will measure any swelling or redness at the injection site. Volunteers will return to the NIH Clinical Center periodically for 40 weeks after inoculation and will provide blood samples. The blood samples will yield information about the safety of the investigational vaccine and will also be assessed to determine levels of HA-directed antibodies produced following vaccination. Participants who receive FluMos-v1 will have oral mucosal samples taken that will be used for research purposes to determine the oral mucosal immune response to the vaccine.